Could a drug for rare blood disorder help pregnant women with severe preeclampsia?

NCT ID NCT06333652

Recruiting now Disease control Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tests ravulizumab (Ultomiris) in 14 pregnant individuals with severe preeclampsia or HELLP syndrome before 34 weeks of pregnancy. The drug aims to block part of the immune system that may drive these dangerous conditions. Researchers will measure blood markers and pregnancy duration to see if it helps.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ravulizumab (Ultomiris)
What this could lead to: If successful, this could point toward a new treatment option for severe preeclampsia and HELLP syndrome, potentially improving outcomes for pregnant individuals.
What could go wrong: This is a very small early-phase trial with only 14 participants, so results may not apply broadly. The drug may not improve pregnancy outcomes or could have unforeseen risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HELLP SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HELLP syndrome Hemolysis preeclampsia severe pre-eclampsia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PREECLAMPSIA

Contacts and locations

Locations

Mayo Clinic Minnesota
RECRUITING

Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.